The average one-year price target for Ligand Pharmaceuticals Incorporated - Equity Right (OTCPK:LGNXZ) has been revised to $0.00 / share. This is an increase of 25.41% from the prior estimate of $0.00 ...

Ligand Pharmaceuticals (LGND) shares have seen a steady climb in recent months, drawing some attention from investors interested in pharmaceutical royalty platforms. With solid gains over the past ...

The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, ...

Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return ...

Ligand Pharmaceuticals (NASDAQ:LGND) is preparing to release its quarterly earnings on Thursday, 2025-11-06. Here's a brief overview of what investors should keep in mind before the announcement.

Ligand Pharmaceuticals (LGND) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Ligand’s top line is being driven by royalties from sales of drugs developed using its Captisol technology, including Amgen’s AMGN blockbuster drug, Kyprolis, and Gilead’s GILD COVID-19 drug, Veklury.

Learn more about whether Avadel Pharmaceuticals plc or Ligand Pharmaceuticals Incorporated is a better investment based on ...